Phreesia, Inc. (PHR) Q2 2025 Earnings Call Transcript Summary
Phreesia, Inc. (PHR) Q2 2025 Earnings Call Transcript Summary
The company achieved positive operating cash flow of $11.1 million and positive free cash flow of $3.7 million.The following is a summary of the Phreesia, Inc. (PHR) Q2 2025 Earnings Call Transcript:
以下是Phreesia, Inc. (PHR) 2025年第二季度業績會摘要：
Financial Performance:
金融業績：
Phreesia reported a Q2 revenue of $102.1 million, up 19% year-over-year.
Adjusted EBITDA reached $6.5 million, showing a significant increase of $18 million from the previous year.
The company achieved positive operating cash flow of $11.1 million and positive free cash flow of $3.7 million.
Phreesia報告了2025年第二季度營業收入爲10210萬美元，同比增長19%。
調整後的EBITDA達到650萬美元，比上年增加了1800萬美元，呈顯著增長。
該公司實現了正向的經營現金流量1110萬美元和正向的自由現金流370萬美元。
Business Progress:
業務進展：
Phreesia reached positive cash flow for the first time as a public company, marking a significant financial milestone.
They also maintained a revenue outlook for FY 2025, ranging between $416 million to $426 million, with an adjusted EBITDA outlook upgrade to $26 million to $31 million.
The company announced a partnership with MEDITECH and availability on the Oracle healthcare marketplace.
Phreesia作爲上市公司首次實現了正向現金流，標誌着重要的財務里程碑。
他們還維持了2025財年的營收預期在41600萬美元至42600萬美元之間，並將調整後的EBITDA預期提升至2600萬美元至3100萬美元。
公司宣佈與MEDITECH合作，並在Oracle醫療保健市場上提供服務。
Opportunities:
機會：
Expectations for continued growth in Average Health Care Service Clients (AHSCs), projecting an increase to approximately 4,200 by FY 2025 and 4,500 by FY 2026.
Growth opportunities in patient activation measures (PAM) through renewal and potential inclusion in new CMS models.
預計通過連續增長的平均醫療保健服務客戶（AHSC）來實現增長，到2025財年約爲4,200個，到2026財年約爲4,500個。
在患者激活措施（PAM）中存在增長機會，通過續約和在新的CMS模型中的潛在納入。
Risks:
風險：
Potential fluctuations in Network Solutions revenue, which can impact overall financial performance due to variability.
由於網絡解決方案收入的波動性可能會對整體財務表現產生影響。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
